JPMorgan downgrades First Citizens stock rating on funding concerns

JPMorgan downgraded First Citizens BancShares to Underweight from Neutral and cut its price target to $2,200 from $2,300, citing funding-cost pressure when the bank repays its approximately $20 billion FDIC note by year-end 2027. First Citizens reported Q3 2026 adjusted EPS of $55.37, 20% above consensus, and revenue of $2.43 billion; it also guided to a mid-3.20% NIM and mid-to-high-single-digit NII growth for Q4 2027, above JPMorgan's estimates of about 3.10% and roughly 5% growth. The board authorized up to $1.2 billion in Class A buybacks through 2027, including 278,828 shares repurchased for $600 million in Q3; shares had risen 13% over the prior week and were near a 52-week high of $2,430.

Analysis

The key exposure is not simply the scheduled 2027 FDIC-note repayment: FCNCA’s current carry also varies with the fed-funds rate. If rates fall toward or below the note’s 3.50% cost, its contribution to earnings could fade before repayment, making the path of NIM more important than the headline repayment date. Replacement funding while pursuing loan growth compounds that sensitivity; deposit pricing and loan-growth discipline are the variables to monitor.

The earnings beat and buyback authorization support near-term sentiment, but neither establishes that forward earnings power can absorb carry normalization. Buybacks may provide a bid, yet should not be treated as a durable offset unless actual repurchases continue without constraining capital flexibility. After the recent rally, the asymmetry looks less favorable: execution on management’s 2027 outlook must remain strong, while even a modest miss could prompt estimates to converge toward JPMorgan’s more cautious view.

Over the next 1–3 months, watch deposit costs, deposit mix, loan growth, and any revision to NIM/NII guidance. Over 6–18 months, the structural question is whether FCNCA can replace the note without materially repricing liabilities or sacrificing loan growth. The bearish case is falsified by sustained delivery near management’s outlook despite lower rates or repayment progress, without deterioration in funding costs. No basis here to treat JPMorgan’s forecast as established fact or to infer a precise fair value.

Key Decisions for Investors

• Avoid chasing FCNCA after the sharp run-up; consider a measured underweight or relative-value position versus a diversified bank basket rather than an unhedged large short. Reassess after the next results and guidance update.
• Set an alert for quarterly NIM/NII, deposit costs and mix, loan growth, and management commentary on note repayment and replacement funding. A widening gap between reported performance and management’s outlook would strengthen the underweight thesis.
• Do not count the buyback authorization as a guaranteed earnings or price offset. Verify actual repurchase pace and capital flexibility; slower repurchases alongside rising funding costs would be a negative signal.
• Reduce or close the underweight if FCNCA sustains its guided NIM/NII trajectory as the note’s contribution fades, or if funding costs stabilize without a material slowdown in loan growth.